FLUNIVAC aims at developing a candidate influenza vaccine based on recombinant Modified Vaccinia virus Ankara viruses (rMVA) encoding both B-cell and T- cell response-inducing proteins, ready to commence Phase I clinical trials.

We focus on influenza A virus since it is the most pathogenic variant to humans and causes all manifestations of human influenza: zoonotic, seasonal and pandemic.